1. Stem cell populations in adult bone marrow: phenotypes and biological relevance for production of somatic stem cells. In: and , eds. Stem Cells in Human Reproduction. Basic Science and Therapeutic Potential, 2nd edn. New York: Informa Healthcare. 2009; 178–188.
2. , , Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental Hematology. 1976; 4: 267–274.
3. , , et al. Mesenchymal stem cells reside within the connective tissues of many organs. Developmental Dynamics. 1995; 202: 137–144.
4. , , et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24: 1294–1301.
5. , , et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143–147.
6. , , In search of the in vivo identity of mesenchymal stem cells. Stem Cells. 2008; 26: 2287–2299.
7. , , Bone regeneration: the stem/progenitor cells point of view. Journal of Cell and Molecular Medicine. 2010; 14: 103–115.
8. , , Human bone marrow native mesenchymal stem cells. Regenerative Medicine. 2008; 3: 731–741.
9. Mesenchymal stem cells. Journal of Orthopaedic Research. 1991; 9: 641–650.
10. , Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair – current views. Stem Cells. 2007; 25: 2896–2902.
11. , , et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466: 829–834.
12. , , et al. Novel markers for the prospective isolation of human MSC. Annals of the New York Academy of Science. 2007; 1106: 262–271.
13. , , et al. Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica. 2009; 94: 173–184.
14. , , et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood. 2011; 117: 5067–5077.
15. , , et al. The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. Haematologica. 2011; 97: 179–183.
16. , , et al. Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions. Stem Cell Research. 2009; 2: 83–94.
17. , Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. European Journal of Immunology. 2008; 38: 1479–1482.
18. , , et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2: 141–150.
19. , , et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood. 2006; 107: 4817–4824.
20. , , . Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunology Letters. 2008; 115: 50–58.
21. , . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105: 1815–1822.
22. , , et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells and Development. 2010; 19: 607–614.
23. , Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Experimental Hematology. 2009; 37: 1445–1453.
24. , , et al. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008; 26: 151–162.
25. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens. 2007; 69: 1–9.
26. , , Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008; 8: 726–736.
27. , , The immunosuppressive properties of mesenchymal stem cells. Transplantation. 2009; 87: S45–S49.
28. , , et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006; 107: 367–372.
29. , , et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells. 2007; 25: 1753–1760.
30. , , et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005; 90: 516–525.
31. , , et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003; 101: 3722–3729.
32. Induction, function and regulation of IL-17-producing T cells. European Journal of Immunology. 2008; 38: 2636–2649.
33. , , T(H)-17 cells in the circle of immunity and autoimmunity. Nature Immunology. 2007; 8: 345–350.
34. , , et al. The Th17 immune response in renal inflammation. Kidney International. 2010; 77: 1070–1075.
35. , , et al. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. Journal of Autoimmunity. 2008; 30: 222–229.
36. , , et al. TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4+ T cell subsets. Cell Immunology. 2008; 253: 23–30.
37. , , et al. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. Investigative Ophthalmology and Visual Science. 2011; 52: 3143–3152.
38. , , et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology. 2010; 185: 302–312.
39. , , et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. European Journal of Immunology. 2011; 41: 2840–2851.
40. , , et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy. 2011; 13: 686–694.
41. , , et al. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. European Journal of Immunology. 2009; 39: 2840–2849.
42. , , et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 2008; 26: 212–222.
43. , , et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006; 24: 74–85.
44. , , et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006; 107: 1484–1490.
45. , , et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008; 111: 1327–1333.
46. , , et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells. 2008; 26: 99–107.
47. , , et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. Journal of Immunology. 2009; 182: 7963–7973.
48. , , et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2008; 26: 279–289.
49. , Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators of Inflammation. 2010; 865601.
50. , , et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One. 2010; 5: e10088.
51. , Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine. 2007; 262: 509–525.
52. , Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007; 110: 3499–3506.
53. , Mesenchymal stem cells and their potential as cardiac therapeutics. Circulation Research. 2004; 95: 9–20.
54. , , Awakening dormant haematopoietic stem cells. Nature Reviews Immunology. 2010; 10: 201–209.
55. , , et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007; 131: 324–336.
56. , , et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008; 3: 301–313.
57. , , et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. Journal of Experimental Medicine. 2009; 206: 2483–2496.
58. , , et al. The STRO-1+ marrow cell population is multipotential. Cells Tissues and Organs. 2002; 170: 73–82.
59. , , et al. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood. 2007; 109: 1743–1751.
60. , , et al. Early ontogeny of the human marrow from long bones: an immunohistochemical study of hematopoiesis and its microenvironment. Blood. 1996; 87: 4109–4119.
61. , Association of alkaline-phosphatase-positive reticulum cells in bone marrow with granulocytic precursors. Journal of Experimental Medicine. 1979; 150: 919–937.
62. , , et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Experimental Hematology. 2002; 30: 783–791.
63. , Uncertainty in the niches that maintain haematopoietic stem cells. Nature Reviews Immunology. 2008; 8: 290–301.
64. , , et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006; 124: 407–421.
65. , , et al. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. Journal of Clinical Investigation. 2008; 118: 1380–1389.
66. , The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. Journal of Experimental Medicine. 2011; 208: 421–428.
67. , , et al. CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions. Nature Immunology. 2011; 12: 391–398.
68. , , et al. Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell. 2008; 3: 364–366.
69. , , et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell. 2011; 147: 1146–1158.
70. , , et al. Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell in Review. 2011; 7: 569–589.
71. , , et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. New England Journal of Medicine. 2001; 344: 385–386.
72. , , et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis and Cartilage. 2002; 10: 199–206.
73. , , et al. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. International Journal of Hematology. 2004; 80: 370–376.
74. , , et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. Journal of Immunology. 2006; 176: 7761–7767.
75. , , et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390–1397.
76. , , et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplantation Proceedings. 2007; 39: 3358–3362.
77. , , et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells, Molecules and Diseases. 2008; 40: 25–32.
78. , , et al. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007; 21: 1992–1999.
79. , , et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. European Journal of Immunology. 2008; 38: 1745–1755.
80. , , et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371: 1579–1586.
81. , , et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplantation. 2009; 43: 245–251.
82. , , et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biology of Blood and Marrow Transplantation. 2010; 16: 1293–1301.
83. , , et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized placebo-controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplantation. 2010; 16(2): 169–170.
84. , ., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation. 2009; 15: 804–811.
85. , , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008; 22: 593–599.
86.In , , et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003; 102: 1548–1549.
87. , , et al. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood. 2004; 103: 3313–3319.
88. , , et al. Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism. Stem Cells. 2007; 25: 798–806.
89. , , et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cell Physiology. 1998; 176: 57–66.
90. , ., et al. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood. 2006; 107: 1878–1887.
91. , , et al. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. Journal of Cell Physiology. 2000; 184: 58–69.
92. , , et al. Regulation of human B lymphopoiesis by the transforming growth factor-beta superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Experimental Hematology. 2008; 36: 587–597.
93. , , et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005; 106: 1755–1761.
94. , , et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis and Rheumatism. 2007; 56: 1175–1186.
95. , , et al. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford). 2008; 47: 22–30.
96. , , et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. Journal of Immunology. 2009; 183: 993–1004.
97. , , et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia. 2009; 52: 1391–1399.
98. , , et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009; 136: 978–989.
99. , , et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009; 27: 1421–1432.
100. , , et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis and Rheumatism. 2005; 52: 1595–1603.
101. , , et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells. 2009; 27: 2624–2635.
102. , , Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells. 2008; 26: 1913–1919.
103. , , et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. Journal of Immunology. 2009; 182: 5994–6002.
104. , , et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. Journal of Neuroimmunology. 2010; 227: 185–189.
105. , , et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iranian Journal of Immunology. 2007; 4: 50–57.
106. , , et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010; 19: 317–322.
107. , , et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Annals of Rheumatic Diseases. 2010; 69: 1423–1429.
108. , , et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis and Rheumatism. 2010; 62: 2467–2475.